How much cash does Immunovant, Inc. generate?

Immunovant, Inc. (IMVT) generated -$407.3M in operating cash flow over the trailing twelve months.

What is Immunovant, Inc.'s free cash flow?

After $8.0K of capital expenditures, Immunovant, Inc.'s free cash flow was -$407.3M over the trailing twelve months, down 8.2% year over year.

Where does Immunovant, Inc.'s cash flow data come from?

Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Immunovant, Inc. IMVT Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q4 '26	TTM Q3 '26	TTM Q2 '26	TTM Q1 '26	TTM Q4 '25
Net income	-$505.61M-22.2%	-$464.2M-21.3%	-$464.69M-43.9%	-$447.3M-64.1%	-$413.84M-59.6%
Depreciation and amortization	$409K+8.5%	$422K+27.1%	$420K+44.3%	$404K+56.6%	$377K+63.2%
Stock-based compensation	$55.72M+12.6%	$56.27M+18.5%	$55.21M+19.9%	$54.54M+24.3%	$49.49M+20.4%
Change in accounts receivable	-$1.01M+70.5%	-$533K-167%	-$214K-127%	-$631K-136%	-$3.43M-171%
Change in accounts payable	——	——	——	——	——
Change in other assets	-$69K-101%	$1.43M-82.3%	$1.39M-82.8%	$9.63M—	$8.27M—
Change in prepaid expenses	-$8.84M-133%	$10.68M—	$18.79M—	$24.64M—	$26.99M—
Non-cash operating lease expense	$99K-25.6%	$95K-73.8%	$93K-85.4%	$91K-90.0%	$133K-88.2%
Net cash from operating activities	-$407.31M-8.4%	-$422.89M-30.1%	-$430.95M-58.6%	-$417.09M-71.6%	-$375.87M-75.5%
Capital expenditures	$8K-98.9%	$201K-71.6%	$381K-42.2%	$577K+16.1%	$759K+111%
Net cash from investing activities	-$8K+98.9%	-$201K+71.6%	-$381K+42.2%	-$577K-16.1%	-$759K-111%
Proceeds from issuance of common stock	$544.19M+20.9%	$994.19M+112%	$476.1M+0.6%	$452.23M-4.3%	$450M-4.8%
Net cash from financing activities	$595.76M+31.1%	$1.04B+19,121%	$480.59M+1.6%	$456.72M-3.3%	$454.49M-3.8%
Effect of exchange rate changes on cash	-$299K—	——	——	——	——
Net increase (decrease) in cash	——	$619.84M—	$48.93M—	$38.91M—	$78.61M—
Income taxes paid	——	——	——	——	——
Depreciation	$409K+8.5%	$422K+27.1%	$420K+44.3%	$404K+56.6%	$377K+63.2%
Accounts payable	——	——	——	——	——
Accrued expenses and other current liabilities	——	——	——	——	——
Increase (Decrease) in Prepaid Expense	-$8.84M-133%	$10.68M—	$18.79M—	$24.64M—	$26.99M—
Operating lease right-of-use asset amortization	$99K-25.6%	$95K-73.8%	$93K-85.4%	$91K-90.0%	$133K-88.2%
Payments Of Stock Issuance Costs	$504K—	$697K—	——	——	——
Leased assets obtained in exchange for operating lease liabilities	$73K—	$152.75K—	——	——	——
Free cash flow	-$407.32M-8.1%	-$423.09M-29.9%	-$431.34M-58.4%	-$417.66M-71.5%	-$376.63M-75.5%
Free cash flow	-$407.32M-8.1%	-$423.09M-29.9%	-$431.34M-58.4%	-$417.66M-71.5%	-$376.63M-75.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Immunovant, Inc. generate?: Immunovant, Inc. (IMVT) generated -$407.3M in operating cash flow over the trailing twelve months.
What is Immunovant, Inc.'s free cash flow?: After $8.0K of capital expenditures, Immunovant, Inc.'s free cash flow was -$407.3M over the trailing twelve months, down 8.2% year over year.
Where does Immunovant, Inc.'s cash flow data come from?: Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.